# A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases

> **NCT02153398** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 55 (actual)

## Conditions studied

- Gastric Ulcer (GU)
- Duodenal Ulcer (DU)
- Anastomotic Ulcer (AU)
- Non-erosive Reflux Esophagitis Disease (NERD)
- Reflux Esophagitis (RE)
- Zollinger-Ellison Syndrome

## Interventions

- **DRUG:** D961H sachet 10 mg
- **DRUG:** D961H capsule 10mg
- **DRUG:** D961H capsule 20 mg

## Key facts

- **NCT ID:** NCT02153398
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2017-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02153398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02153398, "A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02153398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*